Movatterモバイル変換

[0]ホーム
URL:

IN2012DN02693A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02693A
IN2012DN02693AIN2693DEN2012AIN2012DN02693AIN 2012DN02693 AIN2012DN02693 AIN 2012DN02693AIN 2693DEN2012 AIN2693DEN2012 AIN 2693DEN2012AIN 2012DN02693 AIN2012DN02693 AIN 2012DN02693A
Authority
IN
India
Prior art keywords
methods
subject compound
treating
compositions
xii
Prior art date
Application number
Inventor
Brad Buckman
John B Nicholas
Leonid Beigelman
Vladimir Serebryany
Antitsa Dimitrova Stoycheva
Timothy Thrailkill
Scott D Seiwert
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune IncfiledCriticalIntermune Inc
Publication of IN2012DN02693ApublicationCriticalpatent/IN2012DN02693A/en

Links

Classifications

Landscapes

Abstract

The embodiments provide compounds of the general Formulae I, Ia, II, III, IV, V, VI-1, VI-2, VII, VIII, IX, X, XI, and XII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
IN2693DEN20122009-09-282010-09-24IN2012DN02693A (en)

Applications Claiming Priority (5)

Application NumberPriority DateFiling DateTitle
US24646509P2009-09-282009-09-28
US32425110P2010-04-142010-04-14
US34573710P2010-05-182010-05-18
US34623810P2010-05-192010-05-19
PCT/US2010/050298WO2011038293A1 (en)2009-09-282010-09-24Cyclic peptide inhibitors of hepatitis c virus replication

Publications (1)

Publication NumberPublication Date
IN2012DN02693Atrue IN2012DN02693A (en)2015-09-04

Family

ID=43796242

Family Applications (1)

Application NumberTitlePriority DateFiling Date
IN2693DEN2012IN2012DN02693A (en)2009-09-282010-09-24

Country Status (19)

CountryLink
US (1)US20110081315A1 (en)
EP (1)EP2483290A4 (en)
JP (1)JP2013505952A (en)
KR (1)KR20130026410A (en)
CN (2)CN102741270B (en)
AR (1)AR078462A1 (en)
AU (1)AU2010298028A1 (en)
CA (1)CA2775697A1 (en)
CO (1)CO6531497A2 (en)
EA (1)EA201290128A1 (en)
EC (1)ECSP12011845A (en)
IL (1)IL218766A0 (en)
IN (1)IN2012DN02693A (en)
MA (1)MA33720B1 (en)
MX (1)MX2012003500A (en)
PH (1)PH12012500602A1 (en)
TN (1)TN2012000135A1 (en)
TW (1)TW201124137A (en)
WO (1)WO2011038293A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP1924594A2 (en)2005-07-252008-05-28Intermune, Inc.Novel macrocyclic inhibitors of hepatitis c virus replication
EA200801050A1 (en)*2005-10-112008-12-30Интермьюн, Инк. COMPOUNDS AND METHODS OF INHIBITING THE REPLICATION OF VIRAL HEPATITIS C
AP2010005416A0 (en)*2008-04-152010-10-31Intermune IncNovel macrocyclic inhibitors of hepatitis c virus replication.
CA2740728A1 (en)*2008-10-152010-04-22Intermune, Inc.Therapeutic antiviral peptides
US20110082182A1 (en)*2009-10-012011-04-07Intermune, Inc.Therapeutic antiviral peptides
ES2586231T3 (en)*2010-03-032016-10-13Probiodrug Ag Glutaminyl cyclase inhibitors
CA2801584A1 (en)2010-06-072011-12-15Abbvie Inc.Macrocyclic hepatitis c serine protease inhibitors
CA2811025C (en)*2010-09-102018-07-17Shionogi & Co., Ltd.Hetero ring-fused imidazole derivative having ampk activating effect
WO2012054874A1 (en)*2010-10-222012-04-26Intermune, Inc.Novel macrocyclic inhibitors of hepatitis c virus replication
US8957203B2 (en)2011-05-052015-02-17Bristol-Myers Squibb CompanyHepatitis C virus inhibitors
US8691757B2 (en)2011-06-152014-04-08Bristol-Myers Squibb CompanyHepatitis C virus inhibitors
EP2758386A1 (en)*2011-09-222014-07-30Janssen Pharmaceuticals, Inc.Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv
MX2014015265A (en)2012-06-142015-08-12Basf SePesticidal methods using substituted 3-pyridyl thiazole compounds and derivatives for combating animal pests.
UA119315C2 (en)2012-07-032019-06-10Гіліад Фармассет Елелсі HEPATITIS VIRUS INHIBITORS C
KR20150074051A (en)2012-10-192015-07-01브리스톨-마이어스 스큅 컴퍼니Hepatitis c virus inhibitors
WO2014070964A1 (en)2012-11-022014-05-08Bristol-Myers Squibb CompanyHepatitis c virus inhibitors
WO2014071007A1 (en)2012-11-022014-05-08Bristol-Myers Squibb CompanyHepatitis c virus inhibitors
US9643999B2 (en)2012-11-022017-05-09Bristol-Myers Squibb CompanyHepatitis C virus inhibitors
US9409943B2 (en)2012-11-052016-08-09Bristol-Myers Squibb CompanyHepatitis C virus inhibitors
JP6342922B2 (en)2013-03-072018-06-13ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Hepatitis C virus inhibitor
CN105189495A (en)*2013-03-152015-12-23先正达参股股份有限公司Microbicidally active imidazopyridine derivatives
ES2735355T3 (en)2013-03-152019-12-18Gilead Sciences Inc Hepatitis C virus macrocyclic and bicyclic inhibitors
WO2016127859A1 (en)*2015-02-132016-08-18Sunshine Lake Pharma Co., Ltd.Compounds as hepatitis c inhibitors and uses thereof in medicine
CN108314648A (en)*2018-04-122018-07-24苏州康润医药有限公司The synthetic method of the bromo- 7- fluorine isoquinolin of 4-
CN110305018B (en)*2019-06-062022-07-15浙江普洛家园药业有限公司Preparation method of 3-bromo-2-fluoronitrobenzene
CN112358447B (en)*2020-11-162022-04-12苏州康润医药有限公司Synthesis method of 7-fluoroisoquinoline-1-carboxylic acid
CN114105800B (en)*2021-11-252023-09-01杭州国瑞生物科技有限公司Preparation method of 2, 3-diaminomethyl benzoate
CN119143611A (en)*2024-11-152024-12-17浙江大学衢州研究院Continuous preparation method of N-isopropyl p-fluoroaniline

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3547119A (en)1967-12-081970-12-15Baxter Laboratories IncCatheter assembly
US4211771A (en)1971-06-011980-07-08Robins Ronald KTreatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US3798209A (en)*1971-06-011974-03-19Icn Pharmaceuticals1,2,4-triazole nucleosides
US4311137A (en)1980-04-301982-01-19Sherwood Medical Industries Inc.Infusion device
US4531937A (en)1983-01-241985-07-30Pacesetter Systems, Inc.Introducer catheter apparatus and method of use
CS263951B1 (en)*1985-04-251989-05-12Antonin Holy9-(phosponylmethoxyalkyl)adenines and method of their preparation
US4755173A (en)1986-02-251988-07-05Pacesetter Infusion, Ltd.Soft cannula subcutaneous injection set
US5354866A (en)1989-05-231994-10-11Abbott LaboratoriesRetroviral protease inhibiting compounds
US5696270A (en)1989-05-231997-12-09Abbott LaboratoriesIntermediate for making retroviral protease inhibiting compounds
GB8918806D0 (en)*1989-08-171989-09-27Shell Int ResearchChiral compounds,their preparation and use
US5310562A (en)1989-11-221994-05-10Margolin Solomon BComposition and method for reparation and prevention of fibrotic lesions
US5716632A (en)1989-11-221998-02-10Margolin; Solomon B.Compositions and methods for reparation and prevention of fibrotic lesions
US5518729A (en)1989-11-221996-05-21Margolin; Solomon B.Compositions and methods for reparation and prevention of fibrotic lesions
DE10199053I1 (en)1992-12-292002-08-29Abbott Lab Retroviral protease inhibitors
US5545143A (en)1993-01-211996-08-13T. S. I. MedicalDevice for subcutaneous medication delivery
US5624949A (en)*1993-12-071997-04-29Eli Lilly And CompanyProtein kinase C inhibitors
US6693072B2 (en)*1994-06-022004-02-17Aventis Pharmaceuticals Inc.Elastase inhibitors
US5756466A (en)*1994-06-171998-05-26Vertex Pharmaceuticals, Inc.Inhibitors of interleukin-1β converting enzyme
US6090822A (en)1995-03-032000-07-18Margolin; Solomon B.Treatment of cytokine growth factor caused disorders
US6232333B1 (en)1996-11-212001-05-15Abbott LaboratoriesPharmaceutical composition
US6323180B1 (en)*1998-08-102001-11-27Boehringer Ingelheim (Canada) LtdHepatitis C inhibitor tri-peptides
US6277830B1 (en)1998-10-162001-08-21Schering Corporation5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US6608027B1 (en)*1999-04-062003-08-19Boehringer Ingelheim (Canada) LtdMacrocyclic peptides active against the hepatitis C virus
US7256005B2 (en)1999-08-102007-08-14The Chancellor, Masters And Scholars Of The University Of OxfordMethods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
PL359359A1 (en)*2000-04-052004-08-23Schering CorporationMacrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
PL358591A1 (en)*2000-04-192004-08-09Schering CorporationMacrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties
HU229997B1 (en)*2000-07-212015-04-28Dendreon Corp San DiegoPeptides as ns3-serine protease inhibitors of hepatitis c virus
US7244721B2 (en)*2000-07-212007-07-17Schering CorporationPeptides as NS3-serine protease inhibitors of hepatitis C virus
ATE327246T1 (en)*2000-11-202006-06-15Bristol Myers Squibb Co HEPATITIS C TRIPEPTIDE INHIBITORS
ATE409181T1 (en)*2001-05-082008-10-15Univ Yale PROTEOMIMETIC COMPOUNDS AND METHODS
US6867185B2 (en)*2001-12-202005-03-15Bristol-Myers Squibb CompanyInhibitors of hepatitis C virus
US7273885B2 (en)*2002-04-112007-09-25Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases, particularly HCV NS3-NS4A protease
PL215228B1 (en)*2002-05-202013-11-29Bristol Myers Squibb CoHepatitis c virus inhibitors
PL213029B1 (en)*2002-05-202012-12-31Bristol Myers Squibb CoSubstituted cycloalkyl p1' hepatitis c virus inhibitors
MY140680A (en)*2002-05-202010-01-15Bristol Myers Squibb CoHepatitis c virus inhibitors
PL211889B1 (en)*2002-05-202012-07-31Bristol Myers Squibb CoHeterocyclicsulfonamide hepatitis c virus inhibitors
PL199412B1 (en)*2002-10-152008-09-30Boehringer Ingelheim IntRuthenium new complexes as (pre) catalytic agents of permutation reaction, new derivatives of 2-alkoxy-5-nitrostyrene as intermediate compounds and method of their receiving
EP1615947A2 (en)*2003-04-102006-01-18Boehringer Ingelheim International GmbHProcess for preparing macrocyclic compounds
EP1613620A1 (en)*2003-04-112006-01-11Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases, particularly hcv ns3-ns4a protease
ATE422895T1 (en)*2003-04-162009-03-15Bristol Myers Squibb Co MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS
ES2335887T3 (en)*2003-04-182010-04-06Enanta Pharmaceuticals, Inc. MACROCYCLIC QUINOXALINYL COMPOUNDS THAT INHIBIT THE SERINE PROTEASES OF HEPATITIS C.
US7125845B2 (en)*2003-07-032006-10-24Enanta Pharmaceuticals, Inc.Aza-peptide macrocyclic hepatitis C serine protease inhibitors
CN101857631A (en)*2003-10-102010-10-13沃泰克斯药物股份有限公司Serine protease, the particularly inhibitor of HCV NS3-NS4A proteolytic enzyme
US7491794B2 (en)*2003-10-142009-02-17Intermune, Inc.Macrocyclic compounds as inhibitors of viral replication
CA2540858C (en)*2003-10-142009-12-08Intermune, Inc.Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
US7939538B2 (en)*2004-06-282011-05-10Amgen Inc.Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
DE102004033312A1 (en)*2004-07-082006-01-26Boehringer Ingelheim Pharma Gmbh & Co. Kg Continuous metathesis process with ruthenium catalysts
CA2573346C (en)*2004-07-202011-09-20Boehringer Ingelheim International GmbhHepatitis c inhibitor peptide analogs
EP1797111B1 (en)*2004-08-272011-06-22Schering CorporationAcylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease
EP1794179A1 (en)*2004-09-172007-06-13Boehringer Ingelheim International GmbhRing-closing metathesis process in supercritical fluid
WO2006119061A2 (en)*2005-05-022006-11-09Merck & Co., Inc.Hcv ns3 protease inhibitors
US7608592B2 (en)*2005-06-302009-10-27Virobay, Inc.HCV inhibitors
US7601686B2 (en)*2005-07-112009-10-13Bristol-Myers Squibb CompanyHepatitis C virus inhibitors
TWI389908B (en)*2005-07-142013-03-21Gilead Sciences IncAntiviral compounds
AR057456A1 (en)*2005-07-202007-12-05Merck & Co Inc HCV PROTEASA NS3 INHIBITORS
EP1924594A2 (en)2005-07-252008-05-28Intermune, Inc.Novel macrocyclic inhibitors of hepatitis c virus replication
HRP20110885T1 (en)*2005-07-292011-12-31Tibotec Pharmaceuticals MACROCYCLIC HEPATITIS VIRUS INHIBITORS C
PE20070211A1 (en)*2005-07-292007-05-12Medivir Ab MACROCYCLIC COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS
EP2402331A1 (en)*2005-08-022012-01-04Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases
EA200801050A1 (en)*2005-10-112008-12-30Интермьюн, Инк. COMPOUNDS AND METHODS OF INHIBITING THE REPLICATION OF VIRAL HEPATITIS C
US7772183B2 (en)*2005-10-122010-08-10Bristol-Myers Squibb CompanyHepatitis C virus inhibitors
WO2007057317A1 (en)*2005-11-162007-05-24F. Hoffmann-La Roche AgNovel pyrrolidine derivatives as inhibitors of coagulation factor xa
US7728148B2 (en)*2006-06-062010-06-01Enanta Pharmaceuticals, Inc.Acyclic oximyl hepatitis C protease inhibitors
KR20090024834A (en)*2006-07-052009-03-09인터뮨, 인크. New Inhibitors of Hepatitis C Virus Replication
EP2049474B1 (en)*2006-07-112015-11-04Bristol-Myers Squibb CompanyHepatitis c virus inhibitors
CA2657618C (en)*2006-07-132016-10-11Achillion Pharmaceuticals, Inc.4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US7718612B2 (en)*2007-08-022010-05-18Enanta Pharmaceuticals, Inc.Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
CA2656816A1 (en)*2006-08-042008-02-14Enanta Pharmaceuticals, Inc.Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
US20090035267A1 (en)*2007-07-312009-02-05Moore Joel DAcyclic, pyridazinone-derived hepatitis c serine protease inhibitors
US7635683B2 (en)*2006-08-042009-12-22Enanta Pharmaceuticals, Inc.Quinoxalinyl tripeptide hepatitis C virus inhibitors
US20080038225A1 (en)*2006-08-112008-02-14Ying SunTriazolyl acyclic hepatitis c serine protease inhibitors
US7687459B2 (en)*2006-08-112010-03-30Enanta Pharmaceuticals, Inc.Arylalkoxyl hepatitis C virus protease inhibitors
US7662779B2 (en)*2006-08-112010-02-16Enanta Pharmaceuticals, Inc.Triazolyl macrocyclic hepatitis C serine protease inhibitors
US7582605B2 (en)*2006-08-112009-09-01Enanta Pharmaceuticals, Inc.Phosphorus-containing hepatitis C serine protease inhibitors
US7605126B2 (en)*2006-08-112009-10-20Enanta Pharmaceuticals, Inc.Acylaminoheteroaryl hepatitis C virus protease inhibitors
US20090035268A1 (en)*2007-08-012009-02-05Ying SunTetrazolyl acyclic hepatitis c serine protease inhibitors
US20090098085A1 (en)*2006-08-112009-04-16Ying SunTetrazolyl acyclic hepatitis c serine protease inhibitors
US20080107625A1 (en)*2006-11-012008-05-08Bristol-Myers Squibb CompanyInhibitors of Hepatitis C Virus
US8343477B2 (en)*2006-11-012013-01-01Bristol-Myers Squibb CompanyInhibitors of hepatitis C virus
US7772180B2 (en)*2006-11-092010-08-10Bristol-Myers Squibb CompanyHepatitis C virus inhibitors
EA200970493A1 (en)*2006-11-172009-10-30Тиботек Фармасьютикалз Лтд. MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS
EP2125870A4 (en)*2007-02-162011-04-06Boehringer Ingelheim Int INHIBITORS OF NS3 PROTEASE OF HEPATITIS C
US20100074867A1 (en)*2007-03-232010-03-25Schering Corporation Patent Department, K-6-1; 1990P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease
US20090123423A1 (en)*2007-04-262009-05-14Yonghua GaiHydroxyamic analogs as hepatitis c virus serine protease inhibitor
SG174809A1 (en)2007-05-032011-10-28Intermune IncMacrocyclic compounds useful as inhibitors of hepatitis c virus
JP2010526146A (en)*2007-05-042010-07-29ブリストル−マイヤーズ スクイブ カンパニー [6,5] -bicyclic GPR119G protein-coupled receptor agonist
AU2008251425A1 (en)*2007-05-102008-11-20Array Biopharma, Inc.Novel peptide inhibitors of hepatitis C virus replication
US20090005387A1 (en)*2007-06-262009-01-01Deqiang NiuQuinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
BRPI0813733A2 (en)*2007-06-292019-11-05Gilead Sciences Inc compound with hcv inhibitory activity, its pharmaceutical composition and its use.
WO2009014730A1 (en)*2007-07-262009-01-29Idenix Pharmaceuticals, Inc.Macrocyclic serine protease inhibitors
US20090053175A1 (en)*2007-08-242009-02-26Yat Sun OrSubstitute pyrrolidine derivatives
US20090060874A1 (en)*2007-09-052009-03-05Yao-Ling QiuBicyclic pyrrolidine derivatives
US8163693B2 (en)*2007-09-242012-04-24Achillion Pharmaceuticals, Inc.Urea-containing peptides as inhibitors of viral replication
US20090082366A1 (en)*2007-09-262009-03-26Protia, LlcDeuterium-enriched telaprevir
AU2008309589B2 (en)*2007-10-102012-07-05Novartis AgSpiropyrrolidines and their use against HCV and HIV infection
WO2009055335A2 (en)*2007-10-252009-04-30Taigen Biotechnology Co., Ltd.Hcv protease inhibitors
US8383583B2 (en)*2007-10-262013-02-26Enanta Pharmaceuticals, Inc.Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
WO2009067225A2 (en)*2007-11-202009-05-28Concert Pharmaceuticals, Inc.Boceprevir derivatives for the treatment of hcv infections
ES2599927T3 (en)*2007-12-212017-02-06F. Hoffmann-La Roche Ag Process for the preparation of a macrocycle
AP2010005416A0 (en)*2008-04-152010-10-31Intermune IncNovel macrocyclic inhibitors of hepatitis c virus replication.
EP2307434B1 (en)*2008-07-022014-02-12IDENIX Pharmaceuticals, Inc.Compounds and pharmaceutical compositions for the treatment of viral infections
US7906655B2 (en)*2008-08-072011-03-15Bristol-Myers Squibb CompanyHepatitis C virus inhibitors
BRPI0916609A2 (en)*2008-08-072015-08-04Hoffmann La Roche Process for the preparation of a macrocycle
UY32099A (en)*2008-09-112010-04-30Enanta Pharm Inc HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS
AU2009293493B2 (en)*2008-09-172014-09-18Boehringer Ingelheim International GmbhCombination of HCV NS3 protease inhibitor with interferon and ribavirin
US8603737B2 (en)*2008-09-192013-12-10Celgene Avilomics Research, Inc.Methods for identifying HCV protease inhibitors
US20100080770A1 (en)*2008-09-292010-04-01Bristol-Myers Squibb CompanyHepatitis C Virus Inhibitors
US8044087B2 (en)*2008-09-292011-10-25Bristol-Myers Squibb CompanyHepatitis C virus inhibitors
US8563505B2 (en)*2008-09-292013-10-22Bristol-Myers Squibb CompanyHepatitis C virus inhibitors
CA2740728A1 (en)*2008-10-152010-04-22Intermune, Inc.Therapeutic antiviral peptides
AU2009316472B2 (en)*2008-11-202015-07-09Achillion Pharmaceuticals, Inc.Cyclic carboxamide compounds and analogues thereof as of Hepatitis C virus
US20110064694A1 (en)*2009-09-092011-03-17Yale UniversityAnti-hepatitis c activity of meso-tetrakis-porphyrin analogues
US8703938B2 (en)*2009-09-112014-04-22Enanta Pharmaceuticals, Inc.Hepatitis C virus inhibitors
US8927709B2 (en)*2009-09-112015-01-06Enanta Pharmaceuticals, Inc.Hepatitis C virus inhibitors
US8759332B2 (en)*2009-09-112014-06-24Enanta Pharmaceuticals, Inc.Hepatitis C virus inhibitors
US8822700B2 (en)*2009-09-112014-09-02Enanta Pharmaceuticals, Inc.Hepatitis C virus inhibitors
WO2011031904A1 (en)*2009-09-112011-03-17Enanta Pharmaceuticals, IncHepatitis c virus inhibitors
US8815928B2 (en)*2009-09-112014-08-26Enanta Pharmaceuticals, Inc.Hepatitis C virus inhibitors
AU2009352688B2 (en)*2009-09-152014-04-17Taigen Biotechnology Co., Ltd.HCV protease inhibitors
US20110082182A1 (en)*2009-10-012011-04-07Intermune, Inc.Therapeutic antiviral peptides

Also Published As

Publication numberPublication date
WO2011038293A1 (en)2011-03-31
AU2010298028A2 (en)2012-10-04
US20110081315A1 (en)2011-04-07
AU2010298028A1 (en)2012-04-19
TW201124137A (en)2011-07-16
CN105001302A (en)2015-10-28
IL218766A0 (en)2012-06-28
ECSP12011845A (en)2012-06-29
CN102741270B (en)2015-07-22
EP2483290A4 (en)2013-05-01
MA33720B1 (en)2012-11-01
CO6531497A2 (en)2012-09-28
JP2013505952A (en)2013-02-21
CN102741270A (en)2012-10-17
AR078462A1 (en)2011-11-09
EP2483290A1 (en)2012-08-08
EA201290128A1 (en)2013-01-30
PH12012500602A1 (en)2017-08-23
CA2775697A1 (en)2011-03-31
TN2012000135A1 (en)2013-09-19
MX2012003500A (en)2012-08-01
KR20130026410A (en)2013-03-13

Similar Documents

PublicationPublication DateTitle
IN2012DN02693A (en)
MX2009011867A (en)Novel macrocyclic inhibitors of hepatitis c virus replication.
WO2009142842A3 (en)Novel macrocyclic inhibitors of hepatitis c virus replication
MX2012003171A (en)Novel macrocyclic inhibitors of hepatitis c virus replication.
WO2012087976A3 (en)Novel inhibitors of hepatitis c virus replication
TN2009000481A1 (en)Novel peptide inhibitors of hepatitis c virus replication
MX2009008439A (en)Novel inhibitors hepatitis c virus replication.
TW200740851A (en)Novel macrocyclic inhibitors of hepatitis C virus replication
WO2009134616A8 (en)Novel inhibitors of hepatitis c virus replication
WO2008005511A3 (en)Novel inhibitors of hepatitis c virus replication
WO2007047146A3 (en)Inhibitors of viral replication
UA116616C2 (en) HCV SERINE PROTEASE INHIBITORS RECEIVED FROM MACROCYCLIC PROLINE
TN2012000358A1 (en)Hepatitis c virus inhibitors
EP2555622A4 (en)Hepatitis c virus inhibitors
MX2012004032A (en)Compounds for the treatment of hepatitis c.
MY160130A (en)Hepatitis c virus inhibitors
TNSN06308A1 (en)Macrocyclic compounds as inhibitors of viral replication
MX2010010061A (en)Compounds for the treatment of hepatitis c.
TN2010000468A1 (en)Novel macrocyclic inhibitors of hepatitis c virus replication
UA95455C2 (en)Macrocyclic inhibitors of hepatitis c virus replication
TW200611905A (en)Macrocyclic compounds as inhibitors of viral replication
TN2011000089A1 (en)Compounds for the treatment of hepatitis c
CU20090188A7 (en) NEW INHIBITING PEPTIDES OF HEPATITIS C VIRUS REPLICATION
CU20090182A7 (en) NEW MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
[8]ページ先頭
©2009-2025 Movatter.jp